RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL 3 (BEST3): A RANDOMISED CONTROLLED TRIAL COMPARING THE CYTOSPONGE (TM)-FF3 TEST WITH USUAL CARE TO IDENTIFY OESOPHAGEAL PRE-CANCER IN PRIMARY CARE PATIENTS WITH CHRONIC GASTROESOPHAGEAL REFLUX
Volume
158
Pagination
S136 - S136
Journal
GASTROENTEROLOGY
Issue
ISSN
0016-5085
Metadata
Show full item recordAbstract
Meeting Abstract 634 from Crohn's and Colitis Congress, Austin, TX, JAN 23-25, 2020